Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.
Read original at benzingaStocks · News reference
Wall Street loves to make stock selection sound like a combination of advanced calculus, artificial intelligence and whispered conversations with corporate executives in expensive restaurants. It does not have to be
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.
Read original at benzingaCantor Fitzgerald analyst Sarah James reiterates Bioventus (NASDAQ:BVS) with a Overweight and maintains $15 price target.
Read original at benzingaMajor M&A deals include Visa buys BioCatch, Apollo Global nabs EasyJet, QVC emerges from Chapter 11 bankruptcy.
Read original at benzingaTruist Securities analyst Matthew Coad maintains DLocal (NASDAQ:DLO) with a Buy and raises the price target from $17 to $18.
Read original at benzingaThe article discusses Nebius's recent earnings report and its strong performance in the AI infrastructure sector. Nebius showed a 454% revenue growth quarter, causing the stock to surge despite being down 8.28% on the trading day. The piece also covers earnings from DLocal and Nu Holdings, with commentary on AI data center demand trends and infrastructure stocks.
Read original at the-motley-fool